Genetic factors determine extent of bone loss in inflammatory bowel disease

Gastroenterology

Volumn 119, Issue 4, 2000, Pages 909-920

  Schulte, Claudia M S ^a   Dignass, Axel U ^b   Goebell, Harald ^b   Roher, Hans Dietrich ^c   Schulte, Klaus Martin ^c  

^a Division of Endocrinology   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CYTOKINE; DEOXYPYRIDINOLINE; HEAT SHOCK PROTEIN 70; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; PARATHYROID HORMONE; VITAMIN D;

ADULT; ALLELE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; ENTERITIS; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033774343     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.18158     Document Type: Article

References (51)

1. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
2. Bone loss in patients with inflammatory bowel disease is less than expected: A follow-up study
3. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
4. Inflammatory bowel disease: Etiology and pathogenesis
5. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
6. The pathophysiologic roles of interleukin-6 in human disease
7. Bone marrow, cytokines and bone remodeling
8. Role of cytokines in bone resorption
9. Molecular chaperones and disease
10. The different expression of proteins recognized by monoclonal anti-heat shock protein 70 (hsp 70) antibody inhuman colonic diseases
11. Polymorphism of heat-shock protein gene HSP 70-2 in Crohn disease: Possible genetic markers for two forms of Crohn disease
12. Molecular chaperones stimulate bone resorption
13. The Escherischia coli chaperonin 60 (gro EL) is a potent stimulator of osteoclast formation
14. IBD-associated bone loss: Is inflammation the explanation?
15. Effect of experimental colitis on bone metabolism in the rat
16. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
17. The 1993-94 Genethom human genetic linkage map
18. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
19. Inflammation mediated osteopenia in the rat: A new animal model for pathological loss of bone mass
20. Review article: Osteoporosis, corticosteroids and inflammatory bowel disease
21. A controlled study of bone mineral density in patients with inflammatory bowel disease
22. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease
23. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease
24. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease
25. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease
26. Bone loss in patients with inflammatory bowel disease: A prospective study
27. Bone mineral content in patients with Crohn’s disease
28. Colitis causes bone loss in rats through suppression of bone formation
29. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study
30. Rapid bone loss is associated with increased levels of biochemical markers
31. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
32. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis
33. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis
34. Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease
35. Femoral neck osteopenia in patients with inflammatory bowel disease
36. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease
37. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis
38. Gender, age and body weight are the major predictive factors for bone mineral density in Crohn’s disease: A case-control cross-sectional study of 113 patients
39. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease
40. Increased degradation of type I collagen in patients with inflammatory bowel disease
41. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: A population based study
42. Reduced bone density in patients with bowel disease
43. Bone and cytokines: Beyond IL-1, II-6 and TNF-alpha
44. Association of radial bone mineral density with CA repeat polymorphism at the interleukin 6 locus in postmenopausal Japanese women
45. Allelic variation at the Interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine
46. Spontaneous postmenopausal bone loss in different skeletal areas: Followed up for 15 years
47. The effects of menopause on longitudinal bone loss from the spine
48. Obesity and postmenopausal bone loss. The influence of obesity on vertebral density and bone turnover in postmenopausal women
49. Vertebral postmenopausal bone loss is reduced in overweight women: A longitudinal study in 155 early postmenopausal women
50. Variability of vertebral and femoral postmenopausal bone loss: A longitudinal study
51. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation